0001575872-20-000064.txt : 20200319 0001575872-20-000064.hdr.sgml : 20200319 20200319062434 ACCESSION NUMBER: 0001575872-20-000064 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20200319 FILED AS OF DATE: 20200319 DATE AS OF CHANGE: 20200319 FILER: COMPANY DATA: COMPANY CONFORMED NAME: DR REDDYS LABORATORIES LTD CENTRAL INDEX KEY: 0001135951 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-15182 FILM NUMBER: 20726367 BUSINESS ADDRESS: STREET 1: 8-2-337, ROAD NO.3 BANJARA HILLS CITY: HYDERABAD STATE: K7 ZIP: 500-034 BUSINESS PHONE: 91 40 49002900 MAIL ADDRESS: STREET 1: 8-2-337, ROAD NO.3 BANJARA HILLS CITY: HYDERABAD STATE: K7 ZIP: 500-034 6-K 1 drr0201_6k.htm FORM 6-K

 

 

 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

March, 2020

 

Commission File Number 1-15182

 

DR. REDDY’S LABORATORIES LIMITED

(Translation of registrant’s name into English)

 

8-2-337, Road No. 3, Banjara Hills

Hyderabad, Telangana 500 034, India

+91-40-49002900

 

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F  x Form 40-F  ¨

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ______

 

Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______

 

Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

 

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

 

Yes  ¨ No  x

 

If “Yes” is marked, indicate below the file number assigned to registrant in connection with Rule 12g3-2(b): 82-________.

 

 

 

 

 

 

EXHIBITS

 

Exhibit
Number
  Description of Exhibits
     
99.1   Press Release dated March 19, 2020 for Dr. Reddy's Laboratories announces first-to-market launch of Naloxone Hydrochloride Injection USP, 2 mg/2 mL (1 mg/mL) Single-dose Prefilled Syringe in the U.S. Market

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

DR. REDDY’S LABORATORIES LIMITED

(Registrant)

   
Date: March 19, 2020 By: /s/ Sandeep Poddar
    Name: Sandeep Poddar
    Title: Company Secretary

 

 

 

EX-99.1 2 drr0201_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

 

March 19, 2020

 

Corporate Relationship Department National Stock Exchange of India Ltd.
BSE Limited “Exchange Plaza”
Dalal Street, Fort Bandra-Kurla Complex, Bandra (East),
Mumbai – 400 001 Mumbai – 400 051
Fax Nos.: 022-22723121 / 22723719 / Fax Nos.: 022-26598120/ 26598237/
 22722037 / 22722039 26598238
   
Scrip Code: 500124 Scrip Code: DRREDDY-EQ

 

Dear Sirs,

 

Sub: Press Release

 

Please find enclosed a Press Release on “Dr. Reddy's Laboratories announces first-to-market launch of Naloxone Hydrochloride Injection USP, 2 mg/2 mL (1 mg/mL) Single-dose Prefilled Syringe in the U.S. Market.”

 

This is for your information.

 

With regards,

 

Sandeep Poddar

Company Secretary

 

Encl: As above

 

CC:- New York Stock Exchange Inc.(Stock Code: RDY)

 

Classification | PUBLIC

 

 

 

 

    

  CONTACT
DR. REDDY'S LABORATORIES LTD. Investor relationS Media relationS
8-2-337, Road No. 3, Banjara Hills,
Hyderabad - 500034. Telangana, India.

AMIT AGARWAL amita@drreddys.com

(Ph: +91-40-49002135)

APARNA TEKURI

aparnatekuri@drreddys.com

(Ph: +91-40- 49002446)

 

Dr. Reddy's Laboratories announces first-to-market

launch of Naloxone Hydrochloride Injection USP, 2 mg/2 mL (1 mg/mL)
Single-dose Prefilled Syringe in the U.S. Market

 

Hyderabad, India, March 19, 2020 For Immediate Release

 

 

 

Hyderabad, India and Princeton, NJ, USA. March 19, 2020— Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Naloxone Hydrochloride Injection USP, 2 mg/2 mL (1 mg/mL) Single-dose Prefilled Syringe, a therapeutic equivalent generic version of Narcan® (naloxone hydrochloride) Injection USP, approved by the U.S. Food and Drug Administration (USFDA).

 

“We are pleased to bring our second product to market that has been designated as a Competitive Generic Therapy (CGT) by the USFDA,” says Marc Kikuchi, Chief Executive Officer, North America Generics, Dr. Reddy’s Laboratories. “With a CGT designation, we have 180-day CGT exclusivity to market this product.”

 

The Naloxone Hydrochloride Injection USP, 2 mg/2 mL (1 mg/mL) had U.S. sales of approximately $31 million MAT for the most recent twelve months ending in January 2020 according to IQVIA Health*.

 

Dr. Reddy’s Naloxone Hydrochloride Injection USP, 2 mg/2 mL (1 mg/mL) is available in 2 mL single-dose prefilled syringe.

 

Please see full prescribing information.

https://www.drreddys.com/pi/Naloxone_Hydrochloride_Injection_PI.pdf

 

NARCAN® is a trademark of ADAPT Pharma Operations Limited

 

*IQIA Retail and Non-Retail MAT January 2020

RDY-0320-282

 

 

 

About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy’s operates in markets across the globe. Our major markets include – USA, India, Russia & CIS countries, and Europe. For more information, log on to: www.drreddys.com

 

 

 

Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management’s current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words "may", "will", "should", "expects", "plans", "intends", "anticipates", "believes", "estimates", "predicts", "potential", or "continue" and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults , currency exchange rates , interest rates , persistency levels and frequency / severity of insured loss events (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization , including related integration issues.

 

The company assumes no obligation to update any information contained herein.

 

 

 

GRAPHIC 3 drr0201_img01.jpg GRAPHIC begin 644 drr0201_img01.jpg M_]C_X 02D9)1@ ! @ 9 !D #_[ "-1'5C:WD 0 $ 9 " '@ Z M % <@!E ',

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end